Searle Company Ltd · PSX:SEARL
Searle — The Searle Company — Investor Presentation (2022)
23 slides from Searle's investor presentation, 2022
Slide 1: The Searle Company
The Searle Company TO LEAD IN IMPROVING THE QUALITY OF HUMAN LIFE
Slide 2: Subsidiaries of Searle
Subsidiaries of Searle • Searle is 56.32% owned by IBL Group. The Searle • Originally founded in US in 1888 by Gideon D. Searle. Company Limited • Incorporated in Pakistan as a Private Limited Company in 1965 as a subsidiary of G.D. Searle & Co., USA. Listed 74.1% 100% 100% 100% 100% 100% Searle IBL
Slide 3: Our Footprint
Our Footprint TOUCHING LIFE OF MILLIONS BY BRINGING E XCE LLENCE IN C O M M E R C I A L O P E R AT I O N S ND No. 1 2 1Billion Plus Billion Rupee Club i. ii. iii. Cardiovascular Pain Management Gynae Largest Pharmaceutical Company In terms of Product Consumptions(Unit) 3 Brands iv. Cough Suppressant
Slide 4: Achievements
Achievements COMMITMENT TO EXCELLENCE Searle was ranked as the most outstanding company in Healthcare sector of Pakistan as per Asiamoney’s Outstanding Companies Poll, 2018 & 2021. Searle has been part of Forbes Asia’s Best Under A Billion rankings from 2017 to 2019. Searle won Asia’s Best Performin
Slide 5: Pharmaceutical Industry
Pharmaceutical Industry Pharmaceutical sector recorded a revenue of PKR 559bn (USD 3.2 bn) during FY21 with YoY growth of 23% (FY20: PKR 453bn). Market share of Multinational & Market share of Top 100 National companies 3.00% 31.00% No. of Companies Multinational 26 Top 100 Multinational companies N
Slide 6: Our Product Portfolio
Our Product Portfolio M A R K E T I N G A U T H O R I Z AT I O N 22 583 Biotech Local Registration Registration 335 66 Global Enlistments Registration 47 6 Medical Drug Device Manufacturing Registration License
Slide 7: Our Brands
Our Brands LEADING BRANDS IN THEIR THERAPEUTIC AREA Cough • Hydryllin Muscle Relaxant • Nuberol ORS • Peditral Cardiovascular • Extor, Spiromide, Byscard Analgesic • Tramal, Rotec Gastrointestinal • Gravinate, Lomotil, Selanz Antibiotics • Negram Anaemia • Venofer Eye care • Cosopt, Trusopt 7
Slide 8: Our Partners
Our Partners T R U S T O F O U R A F F I L I AT O R S 8
Slide 9: Our Presence
Our Presence Export contributes 10% to our revenue Afghanistan Oman Myanmar Guatemala Sudan Laos Senegal Nigeria Yemen Vietnam Ethiopia Cambodia Ivory Coast Uganda Sri Lanka Kenya Philippines Ghana Cameroon Rwanda Tanzania Maldives Mauritius Existing Market - 15 Future Market - 7
Slide 10: Industry Rankings
Industry Rankings SEARLE IS RANKED NUMBER 2ND IN TERMS OF VOLUME AND RANKEND 5TH IN TERMS OF VALUE 2021 – VOLUME IMS MAT OCT Market Share Growth % 2021 – VALUE IMS MAT OCT Market Share Growth % CAGR GSK 349,229,924 10.66% 2.63% Getz 37,462,694,384 6.29% 21.71% 16.07% Searle 208,058,344 6.35% 7.22% G
Slide 11: Our Revenue
Our Revenue T H E R E V E N U E I N S E A R L E I N C R E A S E D R A P I D LY D U R I N G T H E LAST 21 YEARS 26.2 The revenue of the company grown from 1.3 billion in 2000 to 26.2 billion in 2021, billion representing an average growth rate of 16.20% per annum 1.3 billion 2000 2021
Slide 12: Our Profits
Our Profits THE PROFIT WHICH SEARLE USED TO MAKE IN 2000 NOW R E P R E S E N T S O N LY 5 D AY S O F P R O F I T The profits increased sharply during the last 21 years from just 35.17 million in 2000 to 3.75 billion in the year 3.75 billion 2021, representing an average growth rate of 26.32%. 35.17
Slide 13: Our Strategy
Our Strategy N E W V S . E X I S T I N G P R O D U C T P E R C E N TA G E Old New 36% 32% 31% 28% 29% 28% New products within top 10 Rapid increase in share of top 10 products: 31% 29% 36% 64% - 2016 - 60% 69% 71% - 2018 - 66% - 2021 - 71% 72% 71% 72% 68% 69% 64% 2016 2017 2018 2019 2020 2021 13
Slide 14: Corporate Social Responsibility
Corporate Social Responsibility Our humble CSR efforts • Considering the importance of education and believing it to be a right of every citizen, Searle supports The Citizens Foundation to help them achieve the cause, empowering children to become agents of positive change. • Continuing with our phi
Slide 15: Our R&D Center
Our R&D CENTER I N T E R N AT I O N A L C E N T E R F O R C H E M I C A L A N D B I O L O G I C A L SCIENCES (ICCBS), UNIVERSITY OF KARACHI TSCL has established a state-of- the-art Research & Development Centre at ICCBS Technology Park with first of its kind technology incubator in Pakistan.
Slide 16: Our Collaboration
Our Collaboration Institute of Business Administration, Karachi & N E D U n i v e r s i t y o f E n g i n e e r i n g a n d Te c h n o l o g y • IBA Karachi, signed an agreement with The Searle Company, to establish the Rashid Abdulla Consumer Neuroscience Lab, at IBA Main Campus. • The Company is s
Slide 17: Financial Information
Financial Information 2021 2020 2019 Revenue 16,569,596 16,567,219 14,537,198 SG&A % 31.93% 29.65% 31.53% Operating Profit % 24.48% 23.82% 22.41% Standalone Financials PAT % 12.81% 14.82% 18.17% EPS 9.11 11.25 12.44 Cash Dividend 20.00% 25.00% 25.00% Bonus Dividend 30.00% 0.00% 0.00% 2021 2020 2019
Slide 18: Financial Information
Financial Information 2022 (1Q) 2021 (1Q) 2020 (1Q) Revenue 4,662,307 4,068,860 4,062,321 Standalone Financials SG&A % 29.54% 27.15% 29.57% Operating profit % 21.72% 25.29% 21.16% PAT % 10.02% 14.55% 13.47% EPS 1.95 2.47 2.58 2022 (1Q) 2021 (1Q) 2020 (1Q) Revenue 7,677,861 5,562,484 4,962,130 SG&A %
Slide 19: Thank you
Thank you Add a footer 19
Slide 20: Financial Performance- Standalone
Financial Performance- Standalone 2021 2020 2019 2018 Net Sales 16,569,596 16,567,219 14,537,198 12,675,110 Cost of sales (8,020,891) (8,278,627) (9,690,063) (8,239,863) Gross profit 8,548,705 8,288,592 4,847,135 4,435,247 GP% 52% 50% 33% 35% Distribution costs (4,106,608) (3,802,951) (3,647,507) (3
Slide 21: Financial Performance- Standalone (1st Quarter)
Financial Performance- Standalone (1st Quarter) 2022 (1Q) 2021 (1Q) Variance Var% Net Sales 4,662,307 4,068,860 593,447 15% Cost of sales (2,307,896) (2,057,411) (250,485) 12% Gross profit 2,354,411 2,011,449 342,962 17% GP% 50% 49% Distribution costs (1,106,033) (815,656) (290,377) 36% Administrati
Slide 22: Financial Performance- Consolidated
Financial Performance- Consolidated 2021 2020 2019 2018 Net Sales 26,219,656 20,474,842 18,062,107 16,148,468 Cost of sales (14,028,488) (10,769,089) (9,462,243) (7,817,504) Gross profit 12,191,168 9,705,753 8,599,864 8,330,964 GP% 46% 47% 48% 52% Distribution costs (5,348,136) (4,417,290) (4,284,99
Slide 23: Financial Performance- Consolidated (1st Quarter)
Financial Performance- Consolidated (1st Quarter) 2022 (1Q) 2021 (1Q) Variance Var% Net Sales 7,677,861 5,562,484 2,115,377 38% Cost of sales (4,272,631) (3,002,386) (1,270,245) 42% Gross profit 3,405,230 2,560,098 845,132 33% GP% 44% 46% Distribution costs (1,310,738) (1,015,026) (295,712) 29% Admi